A
Ankasa Regenerative Therapeutics
HOME - Ankasa Regenerative Therapeutics
About Ankasa Regenerative Therapeutics
Ankasa Regenerative Therapeutics focuses on developing advanced protein-based stem cell activation therapies to enhance tissue repair and regeneration. The company's lead product, ART352 L, aims to improve outcomes in spinal fusion surgeries by augmenting autografts used to treat degenerative changes in intervertebral discs. Preclinical data indicate that ART352 L significantly increases bone formation without causing unwanted bone overgrowth, thereby reducing the need for revision surgeries and associated complications. Ankasa's technology has potential applications in various bone reconstructive procedures, including dental and orthopedic implants, knee and hip replacements, fracture repair, and total joint arthroplasty revisions. The company operates in the regenerative medicine market, targeting healthcare providers and patients requiring advanced bone repair solutions. Ankasa generates revenue through venture investments and grants, having raised over $19 million from investors like Avalon Ventures, Heraeus Medical GmbH, Correlation Ventures, and Stanford University, along with over $6 million in grants from The California Institute of Regenerative Medicine (CIRM).
Source: Dealroom company dataNews
Open roles
Ankasa Regenerative Therapeutics in the South San Francisco ecosystem
The Ankasa Regenerative Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Avalon Ventures
Heraeus
Correlation Ventures
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Ankasa Regenerative Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ankasa Regenerative Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


